polatuzumab vedotin: Clinical Trials

9 trials of polatuzumab vedotin, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

3 completed, 2 active not recruiting, 2 not yet recruiting, 1 recruiting. 9 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	9	Completed 3, Active not recruiting 2, Not yet recruiting 2, Recruiting 1, Terminated 1
Phase 2	1	Not yet recruiting 1

Follow polatuzumab vedotin: new trials by email Literature Review of polatuzumab vedotin trials Research Report on polatuzumab vedotin

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5 Surovatamig, Rituximab, Cyclophosphamide - Large B-cell Lymphoma	Phase 3	Not yet recruiting	AstraZeneca	1200	2026-12-22	2026-11-02
A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma	Phase 2 / Phase 3	Not yet recruiting	Merck Sharp & Dohme LLC	470	2026-12-13	2026-11-05
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide, zanubrutinib, rituximab and lenalidomide - Diffuse Large B-Cell Lymphoma	Phase 3	Recruiting	Ruijin Hospital	100	2024-07-29	2024-08-05
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma Glofitamab, Polatuzumab vedotin, Rituximab - Large B-Cell Lymphoma	Phase 3	Active not recruiting	Hoffmann-La Roche	1130	2023-09-18	2026-09-11
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Mosunetuzumab, Polatuzumab vedotin, Tocilizumab - Non-Hodgkin Lymphoma	Phase 3	Active not recruiting	Hoffmann-La Roche	208	2022-04-25	2026-11-03
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) Polatuzumab Vedotin, Mabthera, Ifosfamide - Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma	Phase 3	Completed	GWT-TUD GmbH	306	2021-04-30	2026-06-10
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). Polatuzumab Vedotin, Bendamustine, Rituximab - Diffuse, Large B-Cell, Lymphoma	Phase 3	Terminated	Hoffmann-La Roche	42	2020-07-10	2023-03-03
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Polatuzumab Vedotin, Rituximab, Gemcitabine - Diffuse Large B-Cell Lymphoma	Phase 3	Completed	Hoffmann-La Roche	270	2020-02-07	2025-12-22
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma Polatuzumab Vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma	Phase 3	Completed	Hoffmann-La Roche	1000	2017-11-16	2026-05-08

Conditions studied

Sponsors

Countries

Results publications

NIH funding